Comparative Pharmacology
Head-to-head clinical analysis: ENDEP versus TRIMIPRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDEP versus TRIMIPRAMINE MALEATE.
ENDEP vs TRIMIPRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant